Mitosense
Plymouth, US · Founded 2019 · Delaware corporation
MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.
Founders & leadership
CC
Catherine C. BaucomExecutive
XJ
Xianpeng JiangExecutive
BS
Brent SegalNamed on SEC filing
CR
CARLA R. YORKNamed on SEC filing
XJ
XIANPENG JIANGNamed on SEC filing
AE
ANDREW E. FINNNamed on SEC filing
TW
TIDAL W. MCCOYNamed on SEC filing
CB
CATHERINE BAUCOMNamed on SEC filing
Board
RE
Richard E. WaldoBoard director
VD
Van D. Hipp Jr.Board director
Reported raises · per SEC filings
Form D private placements$4.4M disclosed across 3 rounds · 2020–2024
▶$3.7MraisedMay 2025 · 16 investors · Other Health CareRule 506(b)
▶$3.7MraisedMay 2025 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard E. WaldoDirector
- Brent SegalExecutive Officer, Director
- Catherine C. BaucomExecutive Officer, Director
- Van D. Hipp Jr.Executive Officer, Director
- Xianpeng JiangExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- Minimum investment
- $10K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$435KraisedFeb 2023 · 4 investors · BiotechnologyRule 506(b)
▶$435KraisedFeb 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard E. WaldoDirector
- Catherine BaucomExecutive Officer, Director
- Van D. Hipp, Jr.Executive Officer, Director
- Xianpeng JiangExecutive Officer, Director
- Brent M. SegalExecutive Officer, Director
- Offering amount
- $7.4M
- Amount sold
- $435K
- Minimum investment
- $5K
- Sales commissions
- $120K
- Finders' fees
- $120K
- Proceeds to insiders
- $25K
- Placement agents
- Carolina Securities Inc.
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$340KraisedFeb 2021 · 9 investors · BiotechnologyRule 506(b)
▶$340KraisedFeb 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CARLA R. YORKExecutive Officer
- XIANPENG JIANGExecutive Officer, Director
- BRENT M. SEGALDirector
- ANDREW E. FINNExecutive Officer, Director
- TIDAL W. MCCOYExecutive Officer, Director
- VAN D. HIPP, JR.Executive Officer, Director
- CATHERINE BAUCOMExecutive Officer
- Offering amount
- $5M
- Amount sold
- $340K
- Minimum investment
- $5K
- Sales commissions
- $120K
- Finders' fees
- $120K
- Placement agents
- CAROLINA SECURITIES INC.
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapInfusense7 shared keywordsInfuSense develops an electrochemical sensing technology platform that detects analytes at sub-therapeutic levels, delivering sample analysis results within minutes. The portable device is designed to bring laboratory-scale testing capabilities into a handheld form factor.
Mito Health5 shared keywordsMito Health offers direct-to-consumer health testing and personalized diagnostics, allowing customers to order from 1000+ lab tests, scans, and health kits at transparent, cost-based pricing without requiring a doctor's referral. Members pay a $9/month subscription for access to member pricing, personalized action plans, longitudinal health tracking, and clinician-reviewed guidance through an AI health coach and concierge service.
Sisense5 shared keywordsSisense provides embedded analytics software that enables teams to integrate data visualization and insights into business applications. The platform serves product development teams and enterprises seeking to build data-driven features into their software products.
Companies competing with Mitosense for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Mitosense do?
- MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.
- How much funding has Mitosense raised?
- Mitosense has disclosed $4.4M raised across 3 rounds.
- Where is Mitosense headquartered?
- Mitosense is headquartered in Plymouth, US.